Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
- Segal, B.H.
- Herbrecht, R.
- Stevens, D.A.
- Ostrosky-Zeichner, L.
- Sobel, J.
- Viscoli, C.
- Walsh, T.J.
- Maertens, J.
- Patterson, T.F.
- Perfect, J.R.
- Dupont, B.
- Wingard, J.R.
- Calandra, T
- Kauffman, C.A.
- Graybill, J.R.
- Baden, L.R.
- Pappas, P.G.
- Bennett, J.E.
- Kontoyiannis, D.P.
- Cordonnier, C.
- Viviani, M.A.
- Bille, J.
- Almyroudis, N.G.
- Wheat, L.J.
- Graninger, W.
- Bow, E.J.
- Holland, S.M.
- Kullberg, B.J.
- Dismukes, W.E.
- Pauw, B.E. de
DOIAbstract
Contains fulltext : 69652.pdf (publisher's version ) (Closed access)Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of...
Add to ORKG